Print
Email
Print Edition Stories
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Funding drugs for rare diseases
Pharmaceutical services company Aptuit Inc. announced today that it has finalized an agreement with GlaxoSmithKline for Aptuit to acquire GSK’s Medicines Research Centre in Verona, Italy.
Greenwich, Conn.-based Aptuit said the agreement provides for continued employment of the 500 personnel at the center for Aptuit to provide GSK with research and development services from the facility.
Financial terms of the acquisition and partnership were not disclosed.
“This is a strategic acquisition of GSK’s research business in Verona that further strengthens scientific expertise and capabilities within Aptuit, extending our integrated discovery and development offerings,” said Tim Tyson, chairman and CEO of Aptuit in a press release. Tyson was named chairman and CEO in 2008.
GSK’s divestment of the Verona facility was tied to its February proposal to cease discovery research in select neurosciences areas such as pain and depression.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
